Pacira BioSciences (PCRX) Long-Term Investments (2014 - 2023)

Pacira BioSciences' Long-Term Investments history runs 10 years deep, the most recent figure standing at $2.4 million for Q4 2023.

• On a quarterly basis, Long-Term Investments fell 93.52% year-over-year to $2.4 million in Q4 2023; TTM through Dec 2023 was $2.4 million, a 93.52% decrease from a year earlier, with the FY2023 full-year figure at $2.4 million, down 93.52% from the prior year.
• Long-Term Investments retreated to $2.4 million in Q4 2023 per PCRX's latest filing, from $8.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $70.6 million in Q3 2019 and bottomed at $2.4 million in Q4 2023.
• The 5-year median for Long-Term Investments is $21.4 million (2019), against an average of $25.7 million.
• Across the five-year window, Long-Term Investments soared 1484.13% in 2019 and slumped 93.52% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $11.0 million in 2019, then climbed by 27.78% to $14.0 million in 2020, then jumped by 149.45% to $35.0 million in 2021, then increased by 6.4% to $37.2 million in 2022, then slumped by 93.52% to $2.4 million in 2023.
• Per Business Quant, the three latest PCRX Long-Term Investments figures stand at $2.4 million (Q4 2023), $8.3 million (Q1 2023), and $37.2 million (Q4 2022).